We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

21 hedge funds and large institutions have $4.68M invested in VistaGen Therapeutics in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

24% more funds holding

Funds holding: 17 → 21 (+4)

23% more capital invested

Capital invested by funds: $3.8M → $4.68M (+$875K)

0.12% less ownership

Funds ownership: 10.16% → 10.04% (-0.12%)

Holders
21
Holders Change
+4
Holders Change %
+23.53%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$934K
2
Northern Trust
Northern Trust
Illinois
+$79.4K
3
OAM
Oxford Asset Management
United Kingdom
+$47.5K
4
FAIM
Financial Advocates Investment Management
Washington
+$41.9K
5
Millennium Management
Millennium Management
New York
+$33.8K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$363K
2
UBS Group
UBS Group
Switzerland
-$5.01K
3
SWP
Stratos Wealth Partners
Ohio
-$2K

VTGN Hedge Fund Activity: Q4 2018 in Review

21 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2018, worth a combined $4.68M — up 23% from $3.8M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VTGN positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $934K. The largest seller was Sphera Funds Management, cutting an estimated $363K.

  • 21 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2018, up from 17 in Q3 2018.
  • Funds reported $4.68M of VistaGen Therapeutics stock for Q4 2018, up 23% quarter-over-quarter.
  • 5 funds opened new VistaGen Therapeutics positions in Q4 2018 and 1 closed out, a net change of +4 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2018 was Vanguard Group, an estimated $934K added.
  • The largest VistaGen Therapeutics seller in Q4 2018 was Sphera Funds Management, an estimated $363K sold.

Based on aggregated 13F filings for Q4 2018.